Supernus Pharmaceuticals Inc
SUPN
Market Cap$1.77B
Close$
$89.36
176.9% upside
Current Fair Value
176.9% upsideUndervalued by 176.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.77 Billion |
|---|---|
| Enterprise Value | $1.74 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $1.34 |
| Beta | 0.74 |
| Outstanding Shares | 55,465,403 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 23.8 |
|---|---|
| PEG | 1.98 |
| Price to Sales | 2.93 |
| Price to Book Ratio | 1.79 |
| Enterprise Value to Revenue | 2.63 |
| Enterprise Value to EBIT | 28.47 |
| Enterprise Value to Net Income | 23 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Supernus Pharmaceuticals Inc
CEO: Jack Khattar